In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni announce IPOs, secure new funding, receive FDA clearances, and much more on the road to LSI Europe ‘25 in London (September 7-11).
Granted U.S. Patent 12,372,595, introducing a novel method for MRI that eliminates the need for B0 gradient coils, marking a major industry breakthrough. This software-based approach enables simpler, more portable, and affordable MRI systems without compromising image quality.
Announced the appointment of Lupe Nesbitt as Chief Financial Officer, bringing over 20 years of financial leadership experience in high-growth, innovation-driven companies. In her new role, she will lead financial strategy, HR, compliance, and investor relations as Amsel enters its next phase of growth.
Received FDA 510(k) clearance for its CardioTag wearable sensor device. The CardioTag™ device is the first noninvasive, multimodal sensor to capture high-fidelity seismocardiogram (SCG), electrocardiogram (ECG), and photoplethysmogram (PPG) signals for cardiac function assessment.
Presented new findings demonstrating that its non-invasive Spectris neuromodulation system significantly slows cognitive, functional, and structural decline in Alzheimer’s disease. The results also point to a broad neuroprotective effect, with up to 9.9 months of time saved across clinical and imaging measures.
Announced the first human implantation of its proprietary BCI system. Led by Principal Investigator Jeffrey G. Ojemann, MD, from the University of Washington School of Medicine in Seattle and Co PI Professor Steven C. Cramer from the University of California, Los Angeles, this trial will gather initial safety data and evaluate whether direct cortical electrical stimulation can enhance upper-limb motor recovery in stroke patients.
Introduced a fully functional prototype of its hydrogen-based medical device, a specialized inhaler designed to support double-blind randomized clinical trials in patients with Mild Cognitive Impairment. This marks a major step toward registering the world's first certified hydrogen-based medical device for neurodegenerative conditions.
Awarded a $250,000 grant from the Arizona Commerce Authority and WearTech Applied Research Center to advance product development and early clinical efforts. Part of the funding will support a new collaboration with ASU Impact Lab to refine the AI algorithms behind HemaSense’s real-time bleed detection and alerting technology.
Secured new patents in Japan and China for its novel urea breath test device for Helicobacter Pylori, expanding its existing protections in the US, Europe, and Turkey. This milestone supports the company's efforts to bring accurate, affordable, and accessible breath-based diagnostics to high-prevalence regions worldwide.
Appointed Medal of Honor recipient and retired U.S. Army Lieutenant Colonel Will Swenson to its Board of Directors as the company advances its AI-powered portable scanner for real-time health and environmental diagnostics. Swenson’s leadership supports illumicell AI’s mission to make early, accessible diagnostics available in military, humanitarian, and remote settings worldwide.
Raised approximately $58 million and appointed Raymond W. Cohen to its board of directors. The financing was led by OrbiMed and Marshall Wace, triggered by the company’s recent FDA premarket approval for the CGuard Prime carotid stent.
MAUI Imaging has raised $14 million in a Series D round led by Acertara Acoustic Laboratories to support the commercialization of its FDA-cleared imaging system powered by Computed Echo Tomography (CET). Unlike traditional ultrasound, MAUI’s CET technology uses a concave probe and patented algorithms to visualize anatomy through barriers like bone, gas, and fat, unlocking critical diagnostic insights in trauma, neurosurgery, and interventional radiology.
Secured exclusive sublicense of DirectSync Surgical’s piezoelectric implantable sensor technology for spinal fusion. The company aims to integrate this with its Hive™ Soft Titanium® devices to enable bone stimulation and real-time data monitoring.
Secured over €40 million in non-dilutive grant funding from the European Commission’s IPCEI Tech4cure initiative.The funding will support expansion of its AI-powered PMcardio platform across Europe and the U.S., including further model development and clinical validation.
Announced the pricing of its IPO at $15.00 per share for 5,000,000 shares, with expected gross proceeds of $75 million. Shares are expected to begin trading on the NYSE under the ticker symbol "SI" on July 31, 2025.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy